Published in Arch Gen Psychiatry on November 01, 1999
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis (2009) 1.20
Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging (2007) 1.06
Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience (2008) 0.96
Selective hippocampal cholinergic deafferentation impairs self-movement cue use during a food hoarding task. Behav Brain Res (2007) 0.83
Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. J Alzheimers Dis (2007) 0.83
Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J Alzheimers Dis (2015) 0.83
Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD. PLoS One (2012) 0.82
Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. Alzheimers Dement (2015) 0.82
Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis (2015) 0.78
Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests. Psychopharmacology (Berl) (2004) 0.78
Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology. Dement Geriatr Cogn Disord (2008) 0.78
Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. J Alzheimers Dis (2015) 0.77
Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? Front Psychiatry (2015) 0.77
Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. PLoS One (2016) 0.77
Specific changes of somatostatin mRNA expression in the frontal cortex and hippocampus of diabetic rats. J Anat (2004) 0.77
Memory-enhancing effect of aspirin is mediated through opioid system modulation in an AlCl3-induced neurotoxicity mouse model. Exp Ther Med (2016) 0.75
The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry (1999) 0.75
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology (1994) 5.81
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med (1998) 4.43
Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med (1974) 4.10
Intraneuronal Abeta42 accumulation in human brain. Am J Pathol (2000) 3.83
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology (2003) 3.62
Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 3.22
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A (1998) 2.91
A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci U S A (1999) 2.81
Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet (1995) 2.66
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science (1980) 2.45
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry (1994) 2.41
Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol (1992) 2.19
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
The pathology of Legionnaires' disease. Fourteen fatal cases from the 1977 outbreak in Vermont. Arch Pathol Lab Med (1978) 2.06
Rising mortality from motoneuron disease in the USA, 1962-84. Lancet (1989) 2.05
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol (1999) 2.02
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry (2000) 1.93
Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J Periodontal Res (1999) 1.90
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology (2006) 1.89
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry (1994) 1.84
The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull (1983) 1.81
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry (1986) 1.80
Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry (1989) 1.79
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology (2009) 1.78
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol (1995) 1.69
Collagenolytic activity associated with Bacteroides species and Actinobacillus actinomycetemcomitans. J Periodontal Res (1982) 1.69
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science (1982) 1.63
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry (2006) 1.62
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry (1998) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol (1989) 1.57
Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol (1990) 1.56
Investigation of a fatality from nonoccupational aluminum phosphide exposure: measurement of aluminum in tissue and body fluids as a marker of exposure. J Lab Clin Med (1993) 1.53
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry (1996) 1.52
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry (1997) 1.51
Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol (1978) 1.50
Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol (1988) 1.49
The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry (1995) 1.46
The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry (1997) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res (1992) 1.45
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem (1995) 1.41
Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology (2008) 1.41
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
Precise determination of the unperturbed 8B neutrino spectrum. Phys Rev Lett (2012) 1.39
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry (1998) 1.39
A 50-year-old male with diabetes mellitus, peripheral neuropathy, hypothyroidism, obesity, sleep disorder, pickwickian syndrome, and heart failure. Mt Sinai J Med (1998) 1.38
Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol (1992) 1.38
Elevated cortical zinc in Alzheimer disease. Neurology (2006) 1.38
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry (1999) 1.36
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Results of the DSM-IV mood disorders field trial. Am J Psychiatry (1995) 1.33
Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol (1992) 1.33
Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology (1988) 1.32
The ionic permeability changes during acetylcholine-induced responses of Aplysia ganglion cells. J Gen Physiol (1968) 1.29
Physiologic factors in the selection of patients for superficial temporal artery-to-middle cerebral artery anastomosis. Surgery (1974) 1.28
Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology (1998) 1.26
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (1994) 1.26
Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res (2005) 1.24
Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord (2003) 1.23
The kinetics of osmotic transport through pores of molecular dimensions. Biophys J (1966) 1.23
Postmortem studies in schizophrenia. Schizophr Bull (1998) 1.23
Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry (2007) 1.22